OncoMatch/Clinical Trials/NCT05624099
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Is NCT05624099 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including camrelizumab and Paclitaxel drugs for esophageal neoplasms.
Treatment: camrelizumab · Paclitaxel drugs · Platinum drug — This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Disease stage
Required: Stage IVA, IVB
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Never received any systemic anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, targeted and immunotherapy
Cannot have received: chemotherapy
Never received any systemic anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, targeted and immunotherapy
Cannot have received: targeted therapy
Never received any systemic anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, targeted and immunotherapy
Cannot have received: immunotherapy
Never received any systemic anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, targeted and immunotherapy
Lab requirements
Blood counts
White blood cell count ≥ 3.0×10^9/L; Neutrophil count ≥ 1.0×10^9/L; Platelet count ≥ 80×10^9/L; Hemoglobin ≥ 80 g/L
Kidney function
Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 45mL/min
Liver function
Total bilirubin ≤ 1.5×ULN; ALT ≤2.5×ULN, AST ≤2.5×ULN
Normal function of major organs, including: Routine blood test...Blood biochemical examination: Total bilirubin ≤ 1.5×ULN, ALT ≤2.5×ULN, AST ≤2.5×ULN, Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 45mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify